 | • レポートコード：D0-MOR-AP1235 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、創傷ケア生物製剤の世界市場について調査・分析した資料で、創傷ケア生物製剤の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
Wound care biologics is gaining popularity for the treatment of wounds and burn injuries. Factors such as growing burden of burn injuries, increasing burden of diabetic foot ulcers and government initiatives regarding wound care treatment are driving the growth of the wound care biologics market. The incidence of diabetes among all ages is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. According to the International Diabetes Federation, in 2019, there were around 4.2 million deaths globally due to diabetes. The incidence of chronic wounds, especially foot ulcers is increasing among the diabetic population resulting in the increased usage of wound care biologics products. Therefore, the growing focus toward the development of better treatment options, along with huge burden of diseases is expected to drive the wound care biologics market. However, the high treatment cost is expected to restrain the growth of the global market in the forecast period.
Key Market Trends
Biological Skin Substitutes Segment is Expected to Witness Better Growth Over the Forecast Period
Based on products, the market is segmented into Biological Skin Substitutes and Topical Agents. Biological Skin Substitutes segment is expected to witness better growth due to their wide usage in the treatment of chronic wounds. These skin substitutes have an intact extracellular matrix for structural support. Biological Skin Substitutes are majorly recommended for burn injuries and treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. According to the International Diabetes Federation, in 2019, almost 463 million people (20-79 years) had diabetes and by 2045 this is expected to rise to 700 million. Chronic wounds lead to complications, such as infection, ulceration, and insufficient blood supply. Hence, the increasing burden of diabetes and the growing adoption of these products are the major factors propelling the growth of the wound care biologics market.
North America Dominates the Wound Care Biologics Market
North America is expected to dominate the wound care biologics market during the forecast years. This is mainly attributed to the growing diabetic population and the rising number of burn injury cases in the region. According to the American Burn Association, approximately 450,000 patients receive hospital and emergency room treatment for burns each year. Burn Injury is one of the leading causes of unintentional death in the United States, which leads to increased adoption of wound care biologics by the hospitals or clinics. Hence, increased awareness, rapid adoption of new technologies, and increasing chronic wound cases are expected to positively impact market growth in this region.
Competitive Landscape
The wound care biologics market is competitive and many of the global players are into the market. For instance – ACell, Inc., Integra LifeSciences Corporation, Kerecis, Marine Polymer Technologies, Inc., MiMedx Inc., Misonix, Inc., Mölnlycke Health Care, Smith & Nephew plc and Wright Medical Group N.V. are providing these products across the globe.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Burn Injuries and Road Accidents
4.2.2 Government Initiatives Regarding Wound Care Treatment
4.3 Market Restraints
4.3.1 High Treatment Cost
4.3.2 Stringent Regulatory Guidelines and Challenges Faced by the Manufacturers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Biological Skin Substitutes
5.1.2 Topical Agents
5.2 By Wound Type
5.2.1 Ulcers
5.2.1.1 Diabetic Foot Ulcers
5.2.1.2 Venous Ulcers
5.2.1.3 Pressure Ulcers
5.2.1.4 Other Ulcers
5.2.2 Surgical & Traumatic Wounds
5.2.3 Burns
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ACell, Inc.
6.1.2 Integra LifeSciences Corporation
6.1.3 Kerecis
6.1.4 Marine Polymer Technologies, Inc.
6.1.5 MiMedx Inc.
6.1.6 MISONIX, Inc.
6.1.7 Molnlycke Health Care
6.1.8 Smith & Nephew plc
6.1.9 Wright Medical Group N.V.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS